Clinical Trial Update: Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study of GlaxoSmithKline's Clostridioides difficile vaccine (2904545A) in healthy adults aged 18-45 and 50-70 years; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Clostridium difficile vaccine 2904545A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Clostridium Infections | Phase 1 | Status: COMPLETED | Results posted: 2024-09-23